Raymond James Financial
TGTX icon

Raymond James Financial’s TG Therapeutics TGTX Stock Holding History

Raymond James Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.2M Sell
426,379
-203,566
-32% -$6.07M ﹤0.01% 1736
2025
Q4 		$18.8M Sell
629,945
-44,182
-7% -$1.44M 0.01% 1492
2025
Q3 		$24.4M Sell
674,127
-4,631
-0.7% -$153K 0.01% 1281
2025
Q2 		$24.4M Sell
678,758
-8,342
-1% -$311K 0.01% 1211
2025
Q1 		$27.1M Buy
687,100
+205,111
+43% +$6.9M 0.01% 1085
2024
Q4 		$14.5M Buy
+481,989
New +$13.8M 0.01% 1545

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Raymond James Financial's TGTX Position: Q1 2026 in Review

Raymond James Financial reduced its TG Therapeutics (TGTX) stake by 32% in Q1 2026, selling an estimated $6.07M and leaving 426,379 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Raymond James Financial first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $27.1M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Raymond James Financial held 426,379 shares of TG Therapeutics worth $14.2M as of Q1 2026.
  • Raymond James Financial sold 203,566 TG Therapeutics shares in Q1 2026, an estimated $6.07M.
  • TG Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #1736 holding.
  • Raymond James Financial first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's TG Therapeutics position peaked at $27.1M in Q1 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.